Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zuzana Zachar

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|September 28, 2023
Toward a Unifying Hypothesis for Redesigned Lipid Catabolism as a Clinical Target in Advanced, Treatment-Resistant CarcinomasPaul M Bingham, Zuzana Zachar
Expert Review of Clinical Pharmacology|October 7, 2014
Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapyPaul M Bingham, Shawn D Stuart, Zuzana Zachar
AJR. American Journal of Roentgenology|May 3, 2017
Metabolic PET Imaging in OncologyKiran Kumar Solingapuram Sai, Zuzana Zachar, Paul M Bingham, et al.
Plos One|June 8, 2022
Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613Moises O Guardado Rivas, Shawn D Stuart, Daniel Thach, et al.
Cancer & Metabolism|March 12, 2014
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox processShawn D Stuart, Alexandra Schauble, Sunita Gupta, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 20, 2011
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivoZuzana Zachar, James Marecek, Claudia Maturo, et al.
The Lancet. Oncology|May 13, 2017
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trialAngela Alistar, Bonny B Morris, Rodwige Desnoyer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|September 28, 2023
Toward a Unifying Hypothesis for Redesigned Lipid Catabolism as a Clinical Target in Advanced, Treatment-Resistant CarcinomasPaul M Bingham, Zuzana Zachar
Expert Review of Clinical Pharmacology|October 7, 2014
Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapyPaul M Bingham, Shawn D Stuart, Zuzana Zachar
AJR. American Journal of Roentgenology|May 3, 2017
Metabolic PET Imaging in OncologyKiran Kumar Solingapuram Sai, Zuzana Zachar, Paul M Bingham, et al.
Plos One|June 8, 2022
Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613Moises O Guardado Rivas, Shawn D Stuart, Daniel Thach, et al.
Cancer & Metabolism|March 12, 2014
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox processShawn D Stuart, Alexandra Schauble, Sunita Gupta, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 20, 2011
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivoZuzana Zachar, James Marecek, Claudia Maturo, et al.
The Lancet. Oncology|May 13, 2017
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trialAngela Alistar, Bonny B Morris, Rodwige Desnoyer, et al.
Pageof 1